ESSA Pharma Inc (TSX-V: EPI,NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, has named Ari Brettman as its director, it was reported on Friday.
Presently, Dr Brettman is a Principal in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. He joined Clarus in September 2014. He is presently a member of the board of directors of Praxis Precision Medicines and Anthos Therapeutics and Observer on the board of directors of Talaris Therapeutics.
Dr Brettman completed a residency in internal medicine and a fellowship in cardiology at Massachusetts General Hospital and was also a National Institutes of Health-sponsored post-doctoral fellow at the MGH Center for Systems Biology. He received his MD from Duke University and his AB in History and Science from Harvard College. While a medical student, he was a Sarnoff Cardiovascular Research Foundation fellow at Stanford University, where he studied angiogenesis.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval